MA40875A - 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux - Google Patents
2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreuxInfo
- Publication number
- MA40875A MA40875A MA040875A MA40875A MA40875A MA 40875 A MA40875 A MA 40875A MA 040875 A MA040875 A MA 040875A MA 40875 A MA40875 A MA 40875A MA 40875 A MA40875 A MA 40875A
- Authority
- MA
- Morocco
- Prior art keywords
- quinolein
- diamino
- substituted
- cancer agents
- new anti
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- 150000005010 aminoquinolines Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<!--startfragment-->la présente invention concerne de nouveaux dérivés de 2-amino primaire-4-amino secondaire-quinoléine, leur fabrication, des compositions pharmaceutiques les comprenant et leur utilisation en tant que médicaments. Les composés actifs de la présente invention sont utiles pour le traitement et la prévention de maladies prolifératives néoplasiques et non néoplasiques.<!--endfragment-->
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073325P | 2014-10-31 | 2014-10-31 | |
| PCT/IB2015/002438 WO2016067112A1 (fr) | 2014-10-31 | 2015-10-26 | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux |
| EP15837091.6A EP3212629B1 (fr) | 2014-10-31 | 2015-10-26 | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40875A true MA40875A (fr) | 2017-09-06 |
| MA40875B1 MA40875B1 (fr) | 2019-01-31 |
Family
ID=55404745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40875A MA40875B1 (fr) | 2014-10-31 | 2015-10-26 | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US10722505B2 (fr) |
| EP (1) | EP3212629B1 (fr) |
| JP (1) | JP6588546B2 (fr) |
| KR (1) | KR102548547B1 (fr) |
| CN (1) | CN107148416B (fr) |
| AU (1) | AU2015338844B2 (fr) |
| CA (1) | CA2965262C (fr) |
| CL (1) | CL2017001073A1 (fr) |
| CO (1) | CO2017007325A2 (fr) |
| CR (1) | CR20170177A (fr) |
| CY (1) | CY1121326T1 (fr) |
| DK (1) | DK3212629T3 (fr) |
| DO (1) | DOP2017000107A (fr) |
| EA (1) | EA037119B1 (fr) |
| EC (1) | ECSP17026748A (fr) |
| ES (1) | ES2707125T3 (fr) |
| GE (1) | GEP20207108B (fr) |
| HR (1) | HRP20190107T1 (fr) |
| IL (1) | IL251775B (fr) |
| LT (1) | LT3212629T (fr) |
| MA (1) | MA40875B1 (fr) |
| MY (1) | MY193740A (fr) |
| NI (1) | NI201700052A (fr) |
| PE (1) | PE20191142A1 (fr) |
| PH (1) | PH12017500810A1 (fr) |
| PL (1) | PL3212629T3 (fr) |
| PT (1) | PT3212629T (fr) |
| RS (1) | RS58328B1 (fr) |
| SG (1) | SG11201703479SA (fr) |
| SI (1) | SI3212629T1 (fr) |
| TN (1) | TN2017000168A1 (fr) |
| TR (1) | TR201900148T4 (fr) |
| UA (1) | UA122062C2 (fr) |
| WO (1) | WO2016067112A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3023032A1 (fr) * | 2016-05-04 | 2017-11-09 | Genoscience Pharma | Derives substitues de 2,4-diamino-quinoleine pour leur utilisation dans le traitement de maladies proliferatives |
| US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
| EP3620164A1 (fr) | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | 2,4 diamino-quinoline substituée en tant que nouveau médicament destiné à la fibrose, l'autophagie et des maladies liées aux cathepsines b (ctsb), l (ctsl) et d (ctsd) |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| TW202214244A (zh) * | 2020-08-10 | 2022-04-16 | 國立彰化師範大學 | 具有協同抗癌功效之氯硝柳胺（Ｎｉｃｌｏｓａｍｉｄｅ）和雙硫侖（Ｄｉｓｕｌｆｉｒａｍ）醫藥組合物及其用途 |
| CN112375081B (zh) * | 2020-11-23 | 2022-04-12 | 中国医学科学院医药生物技术研究所 | 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用 |
| CN112876673B (zh) * | 2021-01-25 | 2021-12-24 | 山东大学 | 一种pH响应性纳米共聚物载体及其制备方法和应用 |
| EP4349336A1 (fr) | 2022-10-04 | 2024-04-10 | Genoscience Pharma | Combinaison de composés 2,4-diamino-quinoléine substitués et d'inhibiteurs de mek pour une utilisation dans le traitement de cancers du foie |
| EP4520396A1 (fr) | 2023-09-05 | 2025-03-12 | Genoscience Pharma | Forme cristalline de base libre de la 2-(4-chlorobenzylamino)-4-(4-tert-butylaminopipéridin-1-yl)-quinoléine et ses utilisations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8580301A1 (es) * | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| EP1571146A4 (fr) * | 2002-12-10 | 2010-09-01 | Ono Pharmaceutical Co | Composes heterocycliques contenant de l'azote et leur utilisation medicale |
| EP1601357A4 (fr) * | 2003-03-10 | 2007-10-03 | Schering Corp | Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese |
| PE20191245A1 (es) * | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| SG11201506385WA (en) * | 2013-03-18 | 2015-10-29 | Genoscience Pharma | Quinolines derivatives as novel anticancer agents |
-
2015
- 2015-10-26 LT LTEP15837091.6T patent/LT3212629T/lt unknown
- 2015-10-26 AU AU2015338844A patent/AU2015338844B2/en active Active
- 2015-10-26 US US15/543,504 patent/US10722505B2/en active Active
- 2015-10-26 MY MYPI2017000628A patent/MY193740A/en unknown
- 2015-10-26 PL PL15837091T patent/PL3212629T3/pl unknown
- 2015-10-26 UA UAA201705278A patent/UA122062C2/uk unknown
- 2015-10-26 JP JP2017522809A patent/JP6588546B2/ja active Active
- 2015-10-26 TR TR2019/00148T patent/TR201900148T4/tr unknown
- 2015-10-26 ES ES15837091T patent/ES2707125T3/es active Active
- 2015-10-26 EA EA201790949A patent/EA037119B1/ru unknown
- 2015-10-26 TN TN2017000168A patent/TN2017000168A1/en unknown
- 2015-10-26 CA CA2965262A patent/CA2965262C/fr active Active
- 2015-10-26 SI SI201530566T patent/SI3212629T1/sl unknown
- 2015-10-26 EP EP15837091.6A patent/EP3212629B1/fr active Active
- 2015-10-26 PT PT15837091T patent/PT3212629T/pt unknown
- 2015-10-26 KR KR1020177013639A patent/KR102548547B1/ko active Active
- 2015-10-26 CN CN201580058830.2A patent/CN107148416B/zh active Active
- 2015-10-26 GE GEAP201514494A patent/GEP20207108B/en unknown
- 2015-10-26 SG SG11201703479SA patent/SG11201703479SA/en unknown
- 2015-10-26 WO PCT/IB2015/002438 patent/WO2016067112A1/fr not_active Ceased
- 2015-10-26 RS RS20190110A patent/RS58328B1/sr unknown
- 2015-10-26 CR CR20170177A patent/CR20170177A/es unknown
- 2015-10-26 MA MA40875A patent/MA40875B1/fr unknown
- 2015-10-26 HR HRP20190107TT patent/HRP20190107T1/hr unknown
- 2015-10-26 DK DK15837091.6T patent/DK3212629T3/en active
-
2017
- 2017-04-18 IL IL251775A patent/IL251775B/en active IP Right Grant
- 2017-04-27 DO DO2017000107A patent/DOP2017000107A/es unknown
- 2017-04-28 CL CL2017001073A patent/CL2017001073A1/es unknown
- 2017-04-28 NI NI201700052A patent/NI201700052A/es unknown
- 2017-04-28 EC ECIEPI201726748A patent/ECSP17026748A/es unknown
- 2017-05-02 PH PH12017500810A patent/PH12017500810A1/en unknown
- 2017-07-24 CO CONC2017/0007325A patent/CO2017007325A2/es unknown
- 2017-08-31 PE PE2017001484A patent/PE20191142A1/es unknown
-
2019
- 2019-01-17 CY CY20191100067T patent/CY1121326T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MX2020013853A (es) | Compuestos innovadores. | |
| EA201792047A1 (ru) | Новые соединения | |
| TN2019000136A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| EP3442973A4 (fr) | Nouveaux composés utilisés en tant qu'inhibiteurs de l'autotaxine et compositions pharmaceutiques les comprenant | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| MX389697B (es) | Nuevos derivados de pirazolopirimidina. | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CY1122441T1 (el) | Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους | |
| MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MX392259B (es) | ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a | |
| MX391392B (es) | ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a. | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
| EA202090414A1 (ru) | Соединения и их применение | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| JOP20190183B1 (ar) | معدِلات مستقبلات الاستروجين | |
| JOP20200100A1 (ar) | مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3 | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| MA39337B1 (fr) | Modulateurs de pyrazines de gpr6 | |
| EA201991490A1 (ru) | Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1 | |
| MA44965B1 (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
| EA202191477A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| MA20150350A1 (fr) | Dérivés isoxazolidine | |
| MA39533B1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives |